–Multiple vepdegestrant (ARV-471) studies enrolling globally, including Phase 1, 2, and 3 studies– – Preliminary data from the Phase 1b combination trial of vepdegestrant + palbociclib suggests potential clinical benefit in a heavily pretreated patient population – NEW HAVEN, Conn., May 05, 2023